Filter Results
Clinical Studies
Results filtered:Study status:
Open
Contact Us for the Latest Status
Closed for Enrollment
Contact Us for the Latest Status
-
Prevalence of Various Visual Symptoms in the Pediatric Population
Rochester, Minn.
The primary purpose of this study is determine the frequency of positive visual symptoms including visual snow in pediatric patients seen for general pediatric care as well as for neurologic care.
The secondary purpose is to determine if positive visual symptoms are more common in pediatric patients who also have a self-reported history of headache or migraine.
Closed for Enrollment
-
A Long-Term, Prospective, Observational Study to Evaluate the Safety, Including Cardiovascular Safety, of Fremanezumab in Patients with Migraine in Routine Clinical Practice (PASS)
Rochester, Minn.
The purpose of this study is to evaluate the long-term safety of Fremanezumab in all patients with migraine through evaluation of incidence of all adverse events.
-
Cluster Headache Treatment with Rimegepant-Open Label Pilot Study (Rimegepant)
Rochester, Minn.
The purpose of this study is to investigate the use of rimegepant for the treatment of cluster headache.
-
Interventional, Randomized, Double-blind, Parallel-group, Placebo-controlled Delayed-start Study to Evaluate the Efficacy and Safety of Eptinezumab in Patients with Episodic Cluster Headache (Alleviate)
Rochester, Minn.,
Scottsdale/Phoenix, Ariz.
The purpose of this study is to evaluate treatment effects, including safety, and is intended to show a statistically significant effect on number of attacks during the cluster headache bout.
-
OnabotulinumtoxinA as a Treatment for Hemiplegic Migraine Case Series
Rochester, Minn.
Hemiplegic migraine is a rare subtype of migraine with aura, with symptoms affecting vision, speech and language, hearing, and sensory and motor disturbances. Muscle weakness and hemiplegia are defining characteristics of hemiplegic migraines. Compared to patients with typical migraine with aura, patients with hemiplegic migraine tend to have more prolonged aura symptoms. In some cases, reversible unilateral weakness may last days to weeks. The primary objective of this project is to evaluate the response of hemiplegic migraine patients evaluated at Mayo Clinic to onabotulinumtoxinA treatments.
.